Eli Lilly took part in the biopharmaceutical startup’s $155m series B while Weiqiao Pioneering led a $112m series A-plus round for robotic truck developer DeepWay.

A Man Holding a Blood Tube

Funding

US-based biopharmaceutical therapeutics developer ArriVent Biopharma raised $155m in series B funding from investors including pharmaceutical firm Eli Lilly’s regional fund, Lilly Asia Ventures. The round was co-led by Sofinnova Investments and General Catalyst and included Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, Infinitum Asset Management, OrbiMed, Octagon…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.